EndoChoice Holdings Inc (GI) reported quarterly earnings results on Wednesday, May-4-2016. The company reported $-0.68 earnings per share for the quarter, missing the analyst consensus estimate by $-0.14. Analysts had a consensus of $-0.54. The company posted revenue of $18.46 million in the period, compared to analysts expectations of $18.34 million. The company’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.00 EPS.
Many Wall Street Analysts have commented on EndoChoice Holdings Inc. EndoChoice Holdings Inc was Downgraded by BofA/Merrill to ” Underperform” on Mar 24, 2016. Shares were Reiterated by Stifel on Mar 4, 2016 to “Buy” and Lowered the Price Target to $ 10 from a previous price target of $16 .
EndoChoice Holdings Inc (GI) witnessed a volatile trading activity on Monday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $5.69 and reached the intraday high at $5.7292. The bulls started the profit booking and pushed the shares to intraday low of $5.25. The trading session was marked by a volume range of 60,119 shares exchanging hands. The 52-week high of the shares is $19.689 and the 52-week low is $3.7011. The market cap of the company stands at $144 M and there are 2,60,09,146 shares in public circulation.
In a different news, on Mar 16, 2016, Mark Gilreath (CEO) purchased 20,000 shares at $5.06 per share price. According to the SEC, on Mar 14, 2016, David L Kaufman (director) purchased 89,450 shares at $4.81 per share price. On Mar 11, 2016, J Scott Carter (director) purchased 49,995 shares at $4.66 per share price, according to the Form-4 filing with the securities and exchange commission.
ECPM Holdings LLC is a medical device company. The Company is focused on designing and commercializing a platform of products for gastrointestinal (GI) caregivers. It offers a range of products and services that span single-use devices and infection control products pathology and imaging systems. The Company’s Fuse system an endoscopy system used for visualization of the GI tract and related therapeutic interventions enables a wider field of view for upper and lower endoscopy procedures. The Fuse colonoscope offers a 330? view of the colon during colonoscopy instead of the 140? to 170? view offered by standard colonoscopes. Its CinchPad is used to improve the transport process of endoscopes after use. The Company’s products are used in colonoscopy and esophagogastroduodenoscopy (EGD) and other procedures of the upper GI tract. The Company serves over 2500 GI departments that perform endoscopic procedures.